arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Enliven Therapeutics, Inc.

ELVN Health Care Biotechnology: Pharmaceutical Preparations
$59.32
Today
as of Sep 4, 16:48 ET
Last 30 days +10.34% Jul 28 → Sep 04
$52.32 $54.69 $57.06 $59.43 $61.80 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$59.69
High
$59.89
Low
$58.97
Volume
$1M
Avg Vol
$1M
Mkt Cap
$4.3B
P/E (TTM)
—
Beta
—
52w High
$62.32
52w Low
$14.79
Div Yield
—
Shares Out
$73M

Recent Press Releases & News last 60 days · 9 items

Sep 3 · 20:05 PR PR Newswire
Enliven Therapeutics to Present at Upcoming Investor Conferences
Aug 31 · 22:05 PR PR Newswire
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Aug 18 · 11:01 MT Newswires
William Blair Initiates Enliven Therapeutics at Outperform
▸ Show all 9 press releases & news Free account →

Overview

52-week range
$15
$62
94% of range
Avg surprise (last 3)
+3.1%
Avg reaction (last 2)
-1.5%
0% positive
Latest IV / EM
57%
EM ±8.9% · $60 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-0.80$-0.68$-0.56$-0.44$-0.32 Actual $-0.80Actual $-0.41Actual $-0.51Actual $-0.54Actual $-0.41Actual $-0.48Actual $-0.57Est $-0.51Actual $-0.49Est $-0.53Actual $-0.32Actual $-0.38Est $-0.44Actual $-0.49 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-32M$-30M$-27M$-24M$-21M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-0.49 — — — — financials
Thu May 7, 2026Mar/2026 $-0.38 $-0.44 +13.6% +33.3% -2.2% earnings
Tue Sep 30, 2025Sep 2025 $-0.32 — — — — financials
Wed Aug 13, 2025Jun/2025 $-0.49 $-0.53 +7.5% — — earnings
Wed May 14, 2025Mar/2025 $-0.57 $-0.51 -11.8% — -0.7% earnings
Mon Sep 30, 2024Sep 2024 $-0.48 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.41 — — — — financials
Sun Mar 31, 2024Mar 2024 $-0.54 — — — — financials
Sat Sep 30, 2023Sep 2023 $-0.51 — — — — financials
Fri Jun 30, 2023Jun 2023 $-0.41 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.80 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue————————
Cost of revenue————————
Gross profit————————
Operating income$-37M$-28M—$-25M$-29M$-32M—$-27M
Net income$-32M$-24M—$-20M$-25M$-29M—$-23M
EPS (diluted)$-0.49$-0.38—$-0.32$-0.49$-0.57—$-0.48

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$136M$132M$99M$102M$119M$102M$124M$101M
Inventory————————
Total current assets$907M$463M$475M$483M$496M$294M$318M$297M
Total assets$910M$465M$476M$491M$504M$303M$326M$305M
Long-term debt————————
Total liabilities$15M$11M$17M$15M$15M$14M$16M$17M
Total equity$895M$453M$460M$476M$488M$288M$310M$288M

Implied volatility — last 90 days

53%107%161%215%269% Jun 07 — IV 250% · EM ±34.6%Jun 08 — IV 243% · EM ±32.1%Jun 09 — IV 264% · EM ±33.1%Jun 10 — IV 270% · EM ±31.9%Jun 11 — IV 100% · EM ±11.0%Jun 12 — IV 86% · EM ±8.8%Jun 15 — IV 144% · EM ±10.4%Jun 16 — IV 156% · EM ±9.2%Jun 17 — IV 169% · EM ±7.1%Jun 19 — IV 67% · EM ±14.9%Jun 22 — IV 76% · EM ±15.9%Jun 23 — IV 72% · EM ±14.8%Jun 24 — IV 74% · EM ±14.8%Jun 25 — IV 70% · EM ±13.8%Jun 26 — IV 67% · EM ±12.7%Jun 29 — IV 71% · EM ±12.5%Jun 30 — IV 70% · EM ±12.1%Jul 01 — IV 80% · EM ±13.3%Jul 02 — IV 74% · EM ±12.0%Jul 03 — IV 77% · EM ±12.0%Jul 06 — IV 75% · EM ±10.4%Jul 07 — IV 63% · EM ±8.3%Jul 08 — IV 72% · EM ±9.0%Jul 09 — IV 70% · EM ±8.2%Jul 10 — IV 78% · EM ±8.7%Jul 13 — IV 84% · EM ±7.0%Jul 14 — IV 138% · EM ±10.0%Jul 15 — IV 197% · EM ±11.7%Jul 16 — IV 125% · EM ±5.2%Jul 20 — IV 70% · EM ±16.5%Jul 21 — IV 66% · EM ±15.3%Jul 22 — IV 65% · EM ±14.9%Jul 23 — IV 66% · EM ±14.9%Jul 24 — IV 64% · EM ±14.2%Jul 27 — IV 68% · EM ±14.3%Jul 28 — IV 67% · EM ±13.7%Jul 29 — IV 68% · EM ±13.7%Jul 30 — IV 66% · EM ±13.0%Jul 31 — IV 54% · EM ±10.4%Aug 03 — IV 84% · EM ±14.8%Aug 04 — IV 78% · EM ±13.5%Aug 05 — IV 79% · EM ±13.2%Aug 06 — IV 67% · EM ±10.9%Aug 07 — IV 57% · EM ±8.9%Aug 10 — IV 65% · EM ±9.0%Aug 11 — IV 74% · EM ±9.8%Aug 12 — IV 73% · EM ±9.1%Aug 13 — IV 73% · EM ±8.6%Aug 14 — IV 77% · EM ±8.5%Aug 17 — IV 80% · EM ±6.7%Aug 18 — IV 68% · EM ±4.9%Aug 19 — IV 72% · EM ±4.3%Aug 20 — IV 88% · EM ±3.7%Aug 24 — IV 56% · EM ±11.7%Aug 25 — IV 54% · EM ±11.0%Aug 26 — IV 55% · EM ±11.1%Aug 27 — IV 56% · EM ±11.0%Aug 28 — IV 56% · EM ±10.8%Aug 31 — IV 66% · EM ±11.7%Sep 01 — IV 65% · EM ±11.2%Sep 02 — IV 57% · EM ±9.5%Sep 03 — IV 57% · EM ±9.2%Sep 04 — IV 57% · EM ±8.8%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in